Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2004-01-21
2010-02-16
Goddard, Laura B (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S139100, C435S326000, C435S346000
Reexamination Certificate
active
07662380
ABSTRACT:
The antibody of the present invention has an extremely high binding ability to human ZAQL-1, can neutralize the activity of human ZAQL-1, and inhibits the action of human ZAQL-1. Therefore, the antibody is useful as a preventive or therapeutic agent or a diagnostic agent for, e.g., digestive diseases, diseases associated with angiogenesis, diseases relating to pregnancy, eating disorders, sleeping disorders, seasonal depression, reproductive dysfunction, endocrine diseases, senile dementia, Alzheimer's disease, various disorders caused by aging, cerebral circulatory disorders, head trauma, spinal injury, epilepsy, anxiety, depression, manic depression, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstral syndrome, glaucoma, cancer, AIDS, diabetes, etc.
REFERENCES:
patent: 6485938 (2002-11-01), Sheppard et al.
patent: 7045299 (2006-05-01), Ohtaki et al.
patent: 2002/0115610 (2002-08-01), Zhou et al.
patent: 2002/0172678 (2002-11-01), Ferrara et al.
patent: 2002/0192634 (2002-12-01), Ferrara et al.
patent: 2007/0014799 (2007-01-01), Matsumoto et al.
patent: 2004-043468 (2004-02-01), None
patent: WO 01/16309 (2001-03-01), None
patent: WO 02/00711 (2002-01-01), None
patent: WO 02/06483 (2002-01-01), None
patent: WO 02/36625 (2002-05-01), None
patent: WO 03/066860 (2003-08-01), None
Score sequence search: “20071029—120952—us-542-664-1.rapbm”, Published Applications database, p. 1-11.
Christiansen et al (Mol Cancer Ther, 2004, 3:1493-1501).
Topp et al (Journal of Controlled Release, 1998, 53:15-23).
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Johnstone and Thorpe (Immunochemistry in Practice, 2nd Ed., 1987, Blackwell Scientific Publications, Oxford, pp. 49-50).
Lecouter, J., et al., “EG-VEGF and the Concept of Tissue-Specific Angiogenic Growth Factors”, Seminars inCell&Developmental Biology, (2002), vol. 13, pp. 3-8.
Lecouter, J., et al., “Endocrine Gland-Derived VEGF and the Emerging Hypothesis of Organ-Specific Regulation of Angiogenesis”,Nature Medicine, (2002), vol. 8, No. 9, pp. 913-917.
Lecouter, J., et al., “Identification of an Angiogenic Mitogen Selective for Endocrine Gland Endothelium”,Nature, (2001), vol. 412, pp. 877-884.
Li, M., et al., “Identification of Two Prokineticin cDNAs: Recombinant Proteins Potently Contract Gastrointestinal Smooth Muscle”,Molecular Pharmacology, (2001), vol. 59, No. 4, pp. 692-698.
EBI Database, Database Accession No. Q8TC69, Database UniProt, (2002), XP-002366641.
Masuda, Y., et al., “Isolation and Identification of EG-VEGF/Prokineticins as Cognate Ligands for Two Orphan G-Protein-Coupled Receptors”,Biochemical and Biophysical Research Communications, (2002), vol. 293, No. 1, pp. 396-402.
R. Lin, et al., “Characterization of Endocrine Gland-derived Vascular Endothelial Growth Factor Signaling in Adrenal Cortex Capillary Endothelial Cells”, The Journal of Biological Chemistry, (2002), pp. 8724-8729, vol. 277, No. 10.
Horikoshi Yasuko
Masuda Yasushi
Matsumoto Hirokazu
Ohtaki Tetsuya
Foley & Lardner LLP
Goddard Laura B
Takeda Pharmaceutical Company Limited
LandOfFree
ZAQ ligand-1 antibodies and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ZAQ ligand-1 antibodies and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ZAQ ligand-1 antibodies and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4216547